152 related articles for article (PubMed ID: 38407943)
21. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia.
Mancikova V; Peschelova H; Kozlova V; Ledererova A; Ladungova A; Verner J; Loja T; Folber F; Mayer J; Pospisilova S; Smida M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217767
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
23. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.
Guercio M; Manni S; Boffa I; Caruso S; Di Cecca S; Sinibaldi M; Abbaszadeh Z; Camera A; Ciccone R; Polito VA; Ferrandino F; Reddel S; Catanoso ML; Bocceri E; Del Bufalo F; Algeri M; De Angelis B; Quintarelli C; Locatelli F
Front Immunol; 2021; 12():755639. PubMed ID: 34737753
[TBL] [Abstract][Full Text] [Related]
24. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
25. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
26. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
27. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
28. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A; Koch CE; Liu-Lupo Y; Hellinger RD; Kyung T; Abbott KL; Fröse J; Goulet D; Gordon KS; Eidell KP; Leclerc P; Whittaker CA; Larson RC; Muscato AJ; Yates KB; Dubrot J; Doench JG; Regev A; Vander Heiden MG; Maus MV; Manguso RT; Birnbaum ME; Hemann MT
Nat Commun; 2023 Dec; 14(1):8048. PubMed ID: 38052854
[TBL] [Abstract][Full Text] [Related]
29. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
[No Abstract] [Full Text] [Related]
30. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
31. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse.
Liu L; Ma C; Zhang Z; Witkowski MT; Aifantis I; Ghassemi S; Chen W
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600553
[TBL] [Abstract][Full Text] [Related]
32. Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells.
Willier S; Raedler J; Blaeschke F; Stenger D; Pazos Escudero M; Jurgeleit F; Grünewald TGP; Binder V; Schmid I; Albert MH; Wolf A; Feuchtinger T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938628
[TBL] [Abstract][Full Text] [Related]
33. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Sellner L; Schubert ML; Hückelhoven-Krauss A; Hong J; Zhu L; Kleist C; Eckstein V; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2020; 11():608167. PubMed ID: 33362794
[TBL] [Abstract][Full Text] [Related]
34. The Qi Yin San Liang San decoction enhances anti-CD19 CAR-T cell function in the treatment of B-cell lymphomas.
Dong S; Wang P; Zhang L; Zhang X; Li X; Wang J; Cui X; Lan T; Gao C; Shi Y; Wang W; Wang J; Jiang M
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117109. PubMed ID: 37657771
[TBL] [Abstract][Full Text] [Related]
35. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
37. Serpin B9 controls tumor cell killing by CAR T cells.
Kimman T; Slomp A; Martens A; Grabherr S; Li S; van Diest E; Meeldijk J; Kuball J; Minnema MC; Eldering E; Bovenschen N; Sebestyén Z; Peperzak V
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36931661
[TBL] [Abstract][Full Text] [Related]
38. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
39. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
40. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Agarwal S; Aznar MA; Rech AJ; Good CR; Kuramitsu S; Da T; Gohil M; Chen L; Hong SA; Ravikumar P; Rennels AK; Salas-Mckee J; Kong W; Ruella M; Davis MM; Plesa G; Fraietta JA; Porter DL; Young RM; June CH
Immunity; 2023 Oct; 56(10):2388-2407.e9. PubMed ID: 37776850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
